Cellectis at ESGCT 2026

Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website

Cellectis brings 2 presentations to ESGCT 2026 in Hamburg. Its work centres on TALE-based genome engineering. It covers in vivo base editing of apoc3 that brings triglyceride levels back to normal in animal models and a broader framework for applying the technology.

OrganizationESGCT 2026 Attendance
Cellectis
Paris, France
cellectis.com
Biotech
Gene editing company using TALEN technology for allogeneic CAR T cell therapies and in vivo editing programs.
Poster
Thu Oct 29
2:00pm–4:00pm
In vivo editing of human apoc3 by tale base editor normalizes triglyceride levels in animal models.
Metabolic diseases
Poster
Thu Oct 29
2:00pm–4:00pm
TALE: developing a global framework for genome engineering
Gene Editing

Explore the full ESGCT 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Hamburg. Leave your work email and we’ll be in touch.

Privacy

Download the full ESGCT 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from Cellectis

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction